AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17885017 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + folate supplements during pregnancy
Number of subjects: 584
Study 15231011 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6186
Study 15231011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6186
Study 12116053 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 2.5 mg sublingual tablet
Number of subjects: 6
Study 12116053 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 10 mg sublingual tablet
Number of subjects: 6
Study 12116053 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 0.03 mg IM injection (positive control)
Number of subjects: 6
Study 12116053 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl IM injection (negative control)
Number of subjects: 6
Study 9715843 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI (200 mg every 12 hours) alone for 4 days
Number of subjects: 18
Study 9715843 — intervention group
Group type: EXPERIMENTAL
Intervention: ritonavir (600 mg every 12 hours) alone for 4 days
Number of subjects: 18
Study 9715843 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI with ritonavir under dose-staggering conditions for 4 days
Number of subjects: 18
Study 8785890 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with topical corticosteroids
Number of subjects: 0
Study 8785890 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with anthralin
Number of subjects: 0
Study 8785890 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with calcipotriene ointment
Number of subjects: 0
Study 8785890 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with methotrexate
Number of subjects: 0
Study 8785890 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with UVB
Number of subjects: 0
Study 8785890 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with retinoids
Number of subjects: 0
Study 8785890 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with cyclosporine
Number of subjects: 0
Study 2281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservatively treated patients with pathologic rhizography findings
Number of subjects: 342
Study 2281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservatively treated patients with negative rhizography
Number of subjects: 342
Study 2281376 — intervention group
Group type: COMPARATOR
Intervention: Surgically treated patients
Number of subjects: 342
Study 7364841 — intervention group
Group type: COMPARATOR
Intervention: Negative pi meson (pion) radiotherapy at a dose of at least 2700 peak pion rads, delivered at a rate of 100 to 125 rads daily.
Number of subjects: 108
Study 7364841 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation treatment (control group).
Number of subjects: 108
Study 30725092 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 0
Study 30725092 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone
Number of subjects: 0
Study 28759823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Resource Nurse program (intervention group)
Number of subjects: 396
Study 28759823 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (control group)
Number of subjects: 396
Study 26556603 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (three escalating doses)
Number of subjects: 40
Study 26556603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25193004 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-PTSD treatment
Number of subjects: 34
Study 25193004 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual wait-list
Number of subjects: 34
Study 22571508 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration tourniquet application (during cement fixation only)
Number of subjects: 65
Study 22571508 — intervention group
Group type: COMPARATOR
Intervention: Long duration tourniquet application (from skin incision to just after cement fixation)
Number of subjects: 65
Study 19395466 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg granisetron
Number of subjects: 179
Study 19395466 — intervention group
Group type: COMPARATOR
Intervention: 3 mg granisetron
Number of subjects: 179
Study 17257370 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment (early start)
Number of subjects: 12
Study 17257370 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 15122959 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Toronto
Number of subjects: 0
Study 15122959 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Los Angeles
Number of subjects: 0
Study 12324553 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin (180 microg once weekly + daily ribavirin 1000 or 1200 mg)
Number of subjects: 1121
Study 12324553 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b plus ribavirin (3 million units thrice weekly + daily ribavirin)
Number of subjects: 1121
Study 12324553 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a alone (weekly peginterferon alfa‐2a + daily placebo)
Number of subjects: 1121
Study 12324553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HCV genotype 1 receiving peginterferon alfa‐2a plus ribavirin
Number of subjects: 1121
Study 12324553 — intervention group
Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 receiving interferon alfa‐2b plus ribavirin
Number of subjects: 1121
Study 12324553 — intervention group
Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 receiving peginterferon alfa‐2a alone
Number of subjects: 1121
Study 12324553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HCV genotype 1 and high baseline levels of HCV RNA receiving peginterferon alfa‐2a plus ribavirin
Number of subjects: 1121
Study 12324553 — intervention group
Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 and high baseline levels of HCV RNA receiving interferon alfa‐2b plus ribavirin
Number of subjects: 1121
Study 12324553 — intervention group
Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 and high baseline levels of HCV RNA receiving peginterferon alfa‐2a alone
Number of subjects: 1121
Study 9665239 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE-PDT (4.25 mg/kg)
Number of subjects: 81
Study 9665239 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE-PDT (3.25 mg/kg)
Number of subjects: 81
Study 9665239 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 81
Study 9665239 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE-PDT
Number of subjects: 81
Study 8607303 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied 10 to 120 minutes before heel-lancing
Number of subjects: 112
Study 8607303 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied 10 to 120 minutes before heel-lancing
Number of subjects: 112
Study 2590615 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg 'biphasic' nifedipine taken 12 hourly for 10 days
Number of subjects: 15
Study 811074 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (C)
Number of subjects: 23
Study 811074 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 23
Study 31230016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus Methylprednisolone (RP/MP)
Number of subjects: 100
Study 31230016 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (RP)
Number of subjects: 100
Study 28902084 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy (4 courses for LR, 6 courses for IR and HR) followed by restricted radiotherapy (RT) if partial remission. Low-dose involved field radiotherapy: 21 Gy plus 14 Gy boost for residual disease.
Number of subjects: 165
Study 28902084 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy (6 courses) followed by 21 Gy involved field radiotherapy for HR patients achieving CR.
Number of subjects: 165
Study 24711637 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD solution
Number of subjects: 50
Study 24711637 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD solution
Number of subjects: 50
Study 23873545 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected group (challenged with 10(5) ELD50/0.1 mL of infectious bronchitis virus)
Number of subjects: 90
Study 23873545 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically healthy chicks)
Number of subjects: 90
Study 23873545 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected group
Number of subjects: 90
Study 21318563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Cannon (NC)
Number of subjects: 196
Study 21318563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Cannon (NC) and mini-lozenge
Number of subjects: 196
Study 19703383 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational, coping-oriented therapy programme (PKB)
Number of subjects: 82
Study 19703383 — intervention group
Group type: COMPARATOR
Intervention: Supportive dialogues or occupational rehabilitation programme
Number of subjects: 82
Study 17867915 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20479
Study 17867915 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (novel dosing for elderly patients)
Number of subjects: 20479
Study 17867915 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 20479
Study 15090125 — intervention group
Group type: EXPERIMENTAL
Intervention: Attaining more fruit-juice goals
Number of subjects: 0
Study 15090125 — intervention group
Group type: EXPERIMENTAL
Intervention: Attaining one vegetable goal
Number of subjects: 0
Study 15090125 — intervention group
Group type: EXPERIMENTAL
Intervention: Attaining three general goals
Number of subjects: 0
Study 11701711 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment for 6 days
Number of subjects: 94
Study 11701711 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I treatment for 6 days
Number of subjects: 94
Study 11701711 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment in GHD patients
Number of subjects: 94
Study 11701711 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide or pegvisomant treatment in acromegalic patients for 3 months
Number of subjects: 94
Study 11701711 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 94
Study 9219043 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once a day) plus Pindolol (2.5 mg three times a day)
Number of subjects: 80
Study 9219043 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 mg once a day) plus Placebo
Number of subjects: 80
Study 8279647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6 mg/kg one time or 1 mg/kg, then 6 mg/kg four days later
Number of subjects: 50
Study 8279647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 220 micrograms/kg; 20 micrograms/kg, then 200 micrograms/kg four days later or 20 micrograms/kg, then 400 micrograms/kg four days later
Number of subjects: 50
Study 8279647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) or 420 micrograms/kg of ivermectin
Number of subjects: 50
Study 8279647 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose DEC
Number of subjects: 50
Study 8279647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin groups
Number of subjects: 50
Study 8279647 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 3735143 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual gambling
Number of subjects: 38
Study 3735143 — intervention group
Group type: EXPERIMENTAL
Intervention: Group gambling
Number of subjects: 38
Study 30293166 — intervention group
Group type: EXPERIMENTAL
Intervention: Force of the stream (FOS)
Number of subjects: 102
Study 30293166 — intervention group
Group type: COMPARATOR
Intervention: Standard voiding trial (SVT)
Number of subjects: 102
Study 29779816 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (6 capsules daily, each containing 180 mg EPA and 120 mg DHA)
Number of subjects: 65
Study 29779816 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 65
Study 29779816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 capsules daily)
Number of subjects: 65
Study 29779816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 27756434 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 intervention (evidence-based care bundle)
Number of subjects: 0
Study 27756434 — intervention group
Group type: COMPARATOR
Intervention: Control EDs (no additional support)
Number of subjects: 0
Study 27756434 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 intervention
Number of subjects: 0
Study 27756434 — intervention group
Group type: COMPARATOR
Intervention: Control EDs
Number of subjects: 0
Study 24702577 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC-PRK
Number of subjects: 167
Study 24702577 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 167
Study 24702577 — intervention group
Group type: COMPARATOR
Intervention: LASEK
Number of subjects: 167
Study 24702577 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK, LASEK, MMC-PRK
Number of subjects: 167
Study 22362836 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing (VC) administration of RUDAS
Number of subjects: 42
Study 22362836 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face (FTF) administration of RUDAS
Number of subjects: 42
Study 20409200 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of two deciduous canines
Number of subjects: 32
Study 20409200 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of four deciduous canines
Number of subjects: 32
Study 17431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft
Number of subjects: 64
Study 17431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft
Number of subjects: 64
Study 16213029 — intervention group
Group type: EXPERIMENTAL
Intervention: Any abuse (AA)
Number of subjects: 330
Study 16213029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined abuse (CA)
Number of subjects: 330
Study 16213029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse without physical abuse (SA)
Number of subjects: 330
Study 16213029 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse without sexual abuse (PA)
Number of subjects: 330
Study 16213029 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at study entry
Number of subjects: 330
Study 12198057 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV
Number of subjects: 12
Study 12198057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10203371 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) therapy
Number of subjects: 7
Study 7758177 — intervention group
Group type: COMPARATOR
Intervention: TPA 100 mg i.v. over 3 hours
Number of subjects: 606
Study 7758177 — intervention group
Group type: EXPERIMENTAL
Intervention: r-PA 15-MU single bolus
Number of subjects: 606
Study 7758177 — intervention group
Group type: EXPERIMENTAL
Intervention: r-PA 10-MU bolus followed by 5 MU 30 minutes later
Number of subjects: 606
Study 7758177 — intervention group
Group type: EXPERIMENTAL
Intervention: r-PA 10-MU bolus followed by 10 MU 30 minutes later
Number of subjects: 606
Study 2135709 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 5
Study 2135709 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 5
Study 2135709 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 5
Study 43966 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg, oral application)
Number of subjects: 40
Study 43966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carazolol (5 mg)
Number of subjects: 40
Study 43966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 43966 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Carazolol
Number of subjects: 40
Study 30756456 — intervention group
Group type: EXPERIMENTAL
Intervention: T2*‐weighted (T2*W) MRI
Number of subjects: 10
Study 30756456 — intervention group
Group type: EXPERIMENTAL
Intervention: T2‐weighted (T2W) MRI
Number of subjects: 10
Study 30756456 — intervention group
Group type: COMPARATOR
Intervention: CT imaging
Number of subjects: 10
Study 30756456 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric assessment using MRI
Number of subjects: 10
Study 28420105 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic intervention for 1 year
Number of subjects: 434
Study 28420105 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 434
Study 25920801 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief drinking interventions (varied in intensity over 60 days)
Number of subjects: 254
Study 23511704 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (100-200 mg daily)
Number of subjects: 130
Study 23511704 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily to thrice-daily dosing frequency of isoflavones
Number of subjects: 130
Study 23511704 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol producers
Number of subjects: 130
Study 23511704 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol nonproducers
Number of subjects: 130
Study 21192296 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic climbing
Number of subjects: 28
Study 21192296 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise therapy
Number of subjects: 28
Study 19143531 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole coadministration
Number of subjects: 0
Study 19143531 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 0
Study 17097031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9001 intraocular lens
Number of subjects: 20
Study 17097031 — intervention group
Group type: COMPARATOR
Intervention: CeeOn 911A intraocular lens
Number of subjects: 20
Study 15623271 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Choice
Number of subjects: 2437
Study 15623271 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Choice
Number of subjects: 2437
Study 15623271 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 2437
Study 11239729 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill training program for parents
Number of subjects: 0
Study 11239729 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment condition
Number of subjects: 0
Study 9865671 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (4 g/day for 4 months)
Number of subjects: 42
Study 9865671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7940133 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol 0.5%
Number of subjects: 25
Study 7940133 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 25
Study 3219226 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical assay for estrogen receptor (ER) status in primary tumors and metastases
Number of subjects: 143
Study 29476803 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based combined training (WBC, n=11)
Number of subjects: 41
Study 29476803 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based aerobic training (WBA, n=13)
Number of subjects: 41
Study 29476803 — intervention group
Group type: COMPARATOR
Intervention: Non-periodized physical activity program (CG, n=9)
Number of subjects: 41
Study 26972925 — intervention group
Group type: EXPERIMENTAL
Intervention: siltuximab plus best supportive care (B.S.C.)
Number of subjects: 79
Study 26972925 — intervention group
Group type: EXPERIMENTAL
Intervention: siltuximab
Number of subjects: 79
Study 26972925 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 79
Study 24918629 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume with PEEP (6 mL/kg tidal volume, 5 cm H2O PEEP)
Number of subjects: 86
Study 24918629 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (10 mL/kg tidal volume, 0 cm H2O PEEP)
Number of subjects: 86
Study 22569835 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day added to interferon beta‐1b
Number of subjects: 77
Study 22569835 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1b monotherapy
Number of subjects: 77
Study 20332266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 minutes, 5 days per week)
Number of subjects: 320
Study 20332266 — intervention group
Group type: COMPARATOR
Intervention: Control (usual life-style)
Number of subjects: 320
Study 18525029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow ventriculoperitoneal shunt
Number of subjects: 215
Study 18525029 — intervention group
Group type: COMPARATOR
Intervention: Sham (occluded) shunt
Number of subjects: 215
Study 14749756 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetically labelled trout fish
Number of subjects: 35
Study 14749756 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetically labelled brewers yeast
Number of subjects: 35
Study 14749756 — intervention group
Group type: COMPARATOR
Intervention: Isotopically labelled selenate
Number of subjects: 35
Study 11192305 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin pretreatment (HP)
Number of subjects: 13
Study 11192305 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin pretreatment (NHP)
Number of subjects: 13
Study 9560837 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group (4-week regimen with dietary advice on egg exclusion)
Number of subjects: 55
Study 9560837 — intervention group
Group type: COMPARATOR
Intervention: Control group (general advice only)
Number of subjects: 55
Study 7839499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and anaerobic exercising conditions
Number of subjects: 19
Study 7839499 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic static exercise
Number of subjects: 19